ADMA 📈 ADMA Biologics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0008991046

ADMA: Immune Globulin, Hepatitis B Vaccine, Plasma-Derived Therapeutics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Web URL: https://www.admabiologics.com

Additional Sources for ADMA Stock

ADMA Stock Overview

Market Cap in USD 4,494m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2013-10-17

ADMA Stock Ratings

Growth 5y 73.2%
Fundamental 88.8%
Dividend -
Rel. Strength Industry 2975
Analysts 4.8/5
Fair Price Momentum 20.01 USD
Fair Price DCF 8.67 USD

ADMA Dividends

No Dividends Paid

ADMA Growth Ratios

Growth Correlation 3m 14.5%
Growth Correlation 12m 96.3%
Growth Correlation 5y 65.4%
CAGR 5y 32.66%
CAGR/Mean DD 5y 0.92
Sharpe Ratio 12m 2.40
Alpha 290.17
Beta 0.73
Volatility 67.34%
Current Volume 6941.5k
Average Volume 20d 2772.6k
What is the price of ADMA stocks?
As of December 21, 2024, the stock is trading at USD 17.40 with a total of 6,941,535 shares traded.
Over the past week, the price has changed by -6.40%, over one month by -18.58%, over three months by -12.91% and over the past year by +325.43%.
Is ADMA Biologics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 88.84 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of December 2024 is 20.01. This means that ADMA is currently undervalued and has a potential upside of +15% (Margin of Safety).
Is ADMA a buy, sell or hold?
ADMA Biologics has received a consensus analysts rating of 4.80. Therefor, it is recommend to buy ADMA.
  • Strong Buy: 4
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ADMA stock price target?
According to ValueRays Forecast Model, ADMA ADMA Biologics will be worth about 22 in December 2025. The stock is currently trading at 17.40. This means that the stock has a potential upside of +26.67%.
Issuer Forecast Upside
Wallstreet Target Price 23.5 34.8%
Analysts Target Price 6 -65.5%
ValueRay Target Price 22 26.7%